期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到23,369篇文章
< 1 2 … 250 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Temporal radiomics for non-invasive preoperative prediction of pathologic complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer 认领 引用 被引量：1
1
作者 Sunyi Zheng Shuo Wang +15 位作者 Ziwei Feng Jing Liang Jiaxin Liu Xiaomeng Yang Zhanshuo Zhang Yuechen Cui Jiping Xie Shuxuan Fan Jing Wang Guoqing Liao Haiyu Zhou Zhaoxiang Ye Jianyu Xiao Lei Shi Xiaonan Cui Dongsheng Yue 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第2期294-309,共16页
Objective:This study aimed to develop and validate a temporal radiomics model based on pre-and post-treatment CT scans for the preoperative prediction of pathologic complete response(pCR)in patients with resectable no... Objective:This study aimed to develop and validate a temporal radiomics model based on pre-and post-treatment CT scans for the preoperative prediction of pathologic complete response(pCR)in patients with resectable non-small cell lung cancer(NSCLC)undergoing neoadjuvant chemoimmunotherapy(NCI).Methods:Data from 263 patients with resectable NSCLC who underwent NCI followed by curative surgery and had both pre-and post-treatment CT scans were retrospectively collected.Patients from one hospital were randomly divided into training and internal test sets at a 7:3 ratio,while patients from two other hospitals served as the external test set.Radiomics features were extracted from the CT scans at both timepoints and delta features capturing the temporal changes were calculated.Radiomics models based on different features were developed using the least absolute shrinkage and selection operator for feature selection,followed by logistic regression.Model performance was evaluated using the area under the curve(AUC).Results:The radiomics model based on delta features yielded AUCs of 0.85,0.76,and 0.72 in the training,internal test,and external test sets,respectively,which were superior to the radiomics models based on pre-treatment features(0.74,0.66,and 0.62,respectively)and post-treatment features(0.80,0.76,and 0.65,respectively).By integrating the optimal features from all three feature sources,the combined model achieved further improvements in performance,with AUCs of 0.89,0.85,and 0.78,respectively,across the three sets.Conclusions:A CT-based radiomics model incorporating temporal features from pre-and post-treatment scans shows favorable performance for the non-invasive preoperative estimation of pCR to NCI in patients with NSCLC. 展开更多
关键词 Non-small cell lung cancer radiomics pathologic complete response neoadjuvant therapy computed tomography
暂未订购 下载PDF
Revisiting nature of stage Ⅲ non-small cell lung cancer:Anatomically defined,biologically systemic 认领 引用
2
作者 Guoyin Li Xi Zhang +2 位作者 Xiaolu Fu Xuewen Liu Zewen Song 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2026年第2期209-233,共25页
Stage Ⅲ non-small cell lung cancer(NSCLC) is traditionally viewed as a locally advanced disease based on anatomic imaging. It is increasingly recognized as a systemic illness with localized manifestations, as evidenc... Stage Ⅲ non-small cell lung cancer(NSCLC) is traditionally viewed as a locally advanced disease based on anatomic imaging. It is increasingly recognized as a systemic illness with localized manifestations, as evidenced by high rates of distant recurrence despite aggressive local therapy. Recent landmark trials(e.g., ADAURA, ALINA,PACIFIC, and KEYNOTE 671) have demonstrated that prolonged systemic treatment, including adjuvant targeted therapy in oncogene-driven NSCLC and consolidation immune checkpoint inhibition after chemoradiotherapy,significantly improves survival outcomes. In contrast, intensifying local therapy alone has exhibited limited benefit or even potential harm. Supporting this shift, detection of circulating tumor DNA and circulating tumor cells indicates the presence of micrometastatic disease at the time of diagnosis. We propose an integrated “sandwich”therapeutic framework encompassing three sequential phases: 1) induction with biomarker-guided systemic therapy(e.g., targeted agents or chemoimmunotherapy) to control micrometastases;2) local consolidation with surgery or radiotherapy tailored to the post-induction tumor extent;and 3) systemic consolidation with prolonged maintenance therapy to eradicate residual disease. This approach underscores the necessity of treating stage Ⅲ NSCLC as a systemic disease from the outset, integrating prolonged, biomarker-directed systemic strategies within a multimodal curative-intent framework to address both the local and systemic components of the disease. 展开更多
关键词 Adjuvant targeted therapy circulating tumor DNA micrometastases neoadjuvant immunotherapy sandwich therapy stage III non-small cell lung cancer systemic disease
暂未订购 下载PDF
PRIME:an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer 认领 引用
3
作者 Yu Wang Yong-Bo Xiang +7 位作者 Xiao-Wei Chen Tao Zhang Jian-Yang Wang Wen-Yang Liu Lei Deng Lu-Hua Wang Shu-Geng Gao Nan Bi 《Military Medical Research》 SCIE CAS CSCD 2026年第5期747-765,共19页
Background:Despite the predictive impact of circulating tumor DNA(ctDNA)minimal residual disease(MRD),accurate prediction of failure risk after curative-intent treatments for early-stage or localized non-small cell lu... Background:Despite the predictive impact of circulating tumor DNA(ctDNA)minimal residual disease(MRD),accurate prediction of failure risk after curative-intent treatments for early-stage or localized non-small cell lung cancer(NSCLC)patients to guide personalized therapy remains challenging.This study aimed to develop and validate an interpretable artificial intelligence-assisted model using global data resources.Methods:Liquid biopsy data,blood-based genomic alterations,clinicopathological features,and survival outcomes of stage I-III NSCLC patients who underwent surgery or definitive chemoradiotherapy were collected from six cohorts.PRIME(Progression Risk prediction by Interpretable Machine learning on ctDNA-MRD,Mutations,and clinical-therapeutic features)was trained by 6 machine learning algorithms across four cohorts and validated in two independent cohorts.Model performance was evaluated by the area under the curve(AUC)and interpreted by SHapley Additive exPlanations(SHAP).Whole-exome sequencing(WES)or whole-genome sequencing(WGS)of tumor tissue from 430 stageⅡ-ⅢNSCLC patients and RNA-sequencing(RNA-seq)data from 1149 subjects,sourced from The Cancer Genome Atlas,were used to validate the prognostic effect of mutations identified in peripheral blood and investigate the underlying mechanisms.Results:A global dataset encompassing 781 blood samples from 493 patients was analyzed.Clinical stage,pretreatment ctDNA,post-treatment MRD,blood-based Kelch-like ECH-associated protein 1(KEAP1),serinehreonine kinase 11(STK11),and cyclin-dependent kinase inhibitor 2A(CDKN2A)mutations,and treatment modality were significantly associated with the risk of disease progression and were thereby included in the model training.WES/WGS and RNA-seq confirmed the poor prognostic effect of KEAP1,STK11,and CDKN2A mutations,which were characterized by the suppressive tumor microenvironment and attenuated humoral immunity.The neural network(NN)model exhibited optimal prediction of treatment failure risk in the training(AUC=0.85,95%CI 0.81-0.89)and validation sets(AUC=0.82,95%CI 0.74-0.89).SHAP analysis indicated that MRD(+0.306),treatment modality(+0.128),and pre-treatment ctDNA(+0.043)ranked in the top 3 contributions.NN-PRIME outperformed single liquid biopsy biomarkers and clinical-therapeutic signatures,and demonstrated consistent robustness across different clinical scenarios.High-risk patients identified by NN-PRIME had poorer prognoses but derived significant benefits from adjuvant therapy after surgery.Conclusions:As an interpretable model integrating readily-accessible and crucial clinical-genomic predictors,PRIME achieves enhanced performance,allowing for early outcome prediction,refined risk stratification,and personalized clinical decision-making. 展开更多
关键词 Non-small cell lung cancer Artificial intelligence(AI) Liquid biopsy Machine learning(ML) Circulating tumor DNA Minimal residual disease
暂未订购 下载PDF
Nobiletin inhibits non-small cell lung cancer through TRKC and exhibits a synergistic effect with the HDAC inhibitor 认领 引用
4
作者 Yuanru Wang Fang Fan +7 位作者 Xue Yang Yuqian Li Luyao Li Qiqi Lei Liuyan Xiang Xiaoqian Zhang Yajun Cao Xuejun Li 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2026年第5期592-603,共12页
Approximately 85%of all lung cancer cases are classified as non-small cell lung cancer(NSCLC).Given its poor prognosis and resistance to radiotherapy and chemotherapy,there is an urgent need to elucidate its molecular... Approximately 85%of all lung cancer cases are classified as non-small cell lung cancer(NSCLC).Given its poor prognosis and resistance to radiotherapy and chemotherapy,there is an urgent need to elucidate its molecular mechanisms to develop novel and more effective therapeutic strategies.In prior research,we identified nobiletin from a compound library and confirmed it as a novel natural BH3 mimetic.Nobiletin synergized with vorinostat to induce autophagy and apoptosis in small-cell lung cancer.In the current study,we further demonstrate that nobiletin,either alone or in combination with vorinostat,exerts inhibitory effects on NSCLC.Specifically,the combination of nobiletin and vorinostat suppressed the proliferation of NSCLC A549 cells.Nobiletin,used alone or with vorinostat,induced apoptosis in A549 cells by mimicking BH3-only proteins,which included down-regulating anti-apoptotic proteins such as B-cell lymphoma-2(BCL-2)and MCL-1,up-regulating apoptosis-related proteins Cleaved-Caspase-3 and Cleaved-PARP,and increasing BH3-only protein expression.Nobiletin binding to BCL-2 facilitated the dissociation of the Beclin-1/BCL-2 complex,thereby elevating levels of free Beclin-1.Furthermore,the combination of nobiletin and vorinostat enhanced the expression of LC3A/BII and forkhead box O1(FOXO1),ultimately inducing autophagy in A549 cells.Eukaryotic transcriptome sequencing revealed that the combination treatment primarily inhibits tumor cell proliferation by modulating TRKC protein expression and suppressing phosphorylation of the phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT)/mammalian target of rapamycin(mTOR)signaling pathway.Therefore,our results indicate that nobiletin,a natural BH3 mimetic,synergizes with vorinostat to regulate both apoptosis and autophagy in NSCLC. 展开更多
关键词 Nobiletin Vorinostat Non-small cell lung cancer NTRK3 BH3-only proteins
暂未订购 下载PDF
Huaier Aqueous Extract Combined with Gefitinib Promotes ACSL4-Dependent Ferroptosis and Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer 认领 引用
5
作者 Yi-heng Du Pei Zhang +5 位作者 Qian-qian Xue Zi-hao Wang Xuan Xiang Yao Liu Hao-lei Wang Qiong Zhou 《Current Medical Science》 SCIE CAS CSCD 2026年第1期197-211,共15页
Objective Huaier,a traditional Chinese medicine(TCM)approved by the National Medical Products Administration(NMPA)of China for cancer therapy,demonstrates broad antitumor activity.However,its potential to overcome res... Objective Huaier,a traditional Chinese medicine(TCM)approved by the National Medical Products Administration(NMPA)of China for cancer therapy,demonstrates broad antitumor activity.However,its potential to overcome resistance to gefitinib,a first-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),in non-small cell lung cancer(NSCLC)and the underlying mechanisms remain unclear.This study aimed to determine whether Huaier aqueous extract enhances the efficacy of gefitinib against resistant NSCLC and to elucidate the molecular basis of this effect.Methods Cell proliferation was evaluated using the Cell Counting Kit-8 and colony formation assays.Apoptosis,reactive oxygen species(ROS),and lipid ROS were measured using flow cytometry,and mitochondrial morphology was examined using transmission electron microscopy.RNA sequencing and integrated bioinformatics analyses of GEO datasets were performed to identify ferroptosis-related genes,which were validated by qPCR and Western blotting.The in vivo efficacy was assessed using a PC-9GR xenograft model.Results Huaier aqueous extract significantly enhanced the sensitivity of gefitinib-resistant NSCLC cells to gefitinib in vitro,and suppressed tumor growth in vivo.Mechanistically,the combined treatment activated the ferroptosis pathway,accom-panied by the upregulation of acyl-CoA synthetase long-chain family member 4(ACSL4).Pharmacological inhibition of ferroptosis or ACSL4 partially attenuated the antitumor effect,confirming their key roles in mediating the synergistic activity of Huaier aqueous extract and gefitinib.Conclusions Huaier aqueous extract reversed gefitinib resistance in NSCLC cells by promoting ACSL4-dependent ferrop-tosis,thereby providing a promising therapeutic strategy for improving EGFR-TKI efficacy. 展开更多
关键词 Non-small cell lung cancer(NSCLC) Huaier Ferroptosis Gefitinib resistance ACSL4 Traditional Chinese Medicine
暂未订购 下载PDF
Exosomes-Transferred lncRNA H19 Reverses Osimertinib Resistance by Upregulating PTEN via Sponging miR-148-3p in Non-Small Cell Lung Cancer 认领 引用
6
作者 Weixiang Song Yanbo Zhang +4 位作者 Xubo Shen Qin Yu Yujin Liu Yongchun Yu Rui Chen 《Oncology Research》 SCIE 2026年第6期698-718,共21页
Objective:Osimertinib can selectively inhibit both epidermal growth factor receptor(EGFR)sensitizing and T790M gatekeeper mutations,and has shown remarkable therapeutic effects in patients with lung adenocarcinoma.How... Objective:Osimertinib can selectively inhibit both epidermal growth factor receptor(EGFR)sensitizing and T790M gatekeeper mutations,and has shown remarkable therapeutic effects in patients with lung adenocarcinoma.However,almost all patients inevitably develop drug resistance.Herein,we sought to clarify the roles of exosomal lncRNA H19 in modulating osimertinib resistance,focusing on the PI3K-PTEN-Akt signaling axis.Methods:Functional assays,including cell viability assay,colony formation,cell apoptosis and xenograft mouse,employed in evaluate the effects of exosomal lncRNA H19 on cell growth and apoptosis.RNA quantitation and western blot were adopted to demonstrate the regulatory roles of exosomal lncRNA H19 in PI3K-PTEN-Akt signaling pathway.Immunofluorescence was applied to obverse the function and distribution of exosomes.Furthermore,dual-luciferase reporter analysis combined with RNA immunoprecipitation(RIP)was applied to verify the molecular interaction between lncRNA H19 and phosphatase and tensin homolog(PTEN).Results:LncRNA H19 exhibited obviously decreased expression in H1975R cells and their secreted exosomes.Overexpression of H19 enhances the cytotoxicity of osimertinib,inhibits the growth of H1975R cells,and promotes apoptosis.Conversely,H19 silencing promotes osimertinib resistance in H1975 cells and enhances the cell-resistant phenotype.Furthermore,exosome-transferred lncRNA H19 sponged miR-148-3p to augment PTEN expression,which in turn inactivated the PI3K-Akt signaling pathway and ultimately induced cell apoptosis.Conclusion:Exosome-encapsulated lncRNA H19 can be delivered to osimertinib-resistant H1975R cells,thereby reversing resistance through the miR-148-3p/PTEN/PI3K-Akt axis.Our results uncover a potential therapeutic approach to surmount osimertinib resistance in lung cancer. 展开更多
关键词 lncRNA H19 phosphatase and tensin homolog(PTEN) exosomes osimertinib non-small cell lung cancer
暂未订购 下载PDF
Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage Ⅲ non-small cell lung cancer 认领 引用
7
作者 Yuzhen Cui Jingdong Xu +6 位作者 Junxu Wen Jianfeng Peng Jiangao Ren Ailing Liu Xiangjiao Meng Zhaoqin Huang Anwen Liu 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第6期865-887,共23页
The integration of immune checkpoint inhibitors has transformed the therapeutic landscape for patients with resectable and potentially resectable stage III non-small cell lung cancer,providing unprecedented opportunit... The integration of immune checkpoint inhibitors has transformed the therapeutic landscape for patients with resectable and potentially resectable stage III non-small cell lung cancer,providing unprecedented opportunities for curative treatment.Several trials have investigated immune checkpoint inhibitors,either alone or in combination with chemotherapy or radiotherapy,as neoadjuvant and/or adjuvant approaches for resectable and potentially resectable stage III non-small cell lung cancer.This comprehensive review elaborates and deeply analyzes the evolving evidence from landmark clinical trials and emerging treatment strategies.Despite these promising outcomes,significant challenges remain,including optimal treatment modality selection,controversy about adjuvant immunotherapy for patients who have already achieved a pathologic complete response,appropriate endpoint evaluation,and biomarker identification.This review also discusses future directions for optimizing immunotherapy integration in patients with resectable stage III non-small cell lung cancer,emphasizing the need for personalized treatment approaches to maximize patient benefit while addressing unanswered clinical questions. 展开更多
关键词 Non-small cell lung cancer immunotherapy chemotherapy radiotherapy resectable potentially resectable biomarkers
暂未订购 下载PDF
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer:a prospective,multicenter,non-interventional study(FLOURISH) 认领 引用
8
作者 Lisha Shen Dongqing Lv +22 位作者 Ke-Jing Tang Jun Zhao Dan Zhu Yanqiu Zhao Ke Wang Yan Wang Zhigang Cai Ligang Xing Ke Xie Jiuwei Cui Lin Mu Chao Cao Liren Ding Peifeng Chen Jun Liang Yongmin Ding Liqin Lu Jiliang Zhang Xinmin Yu Li Chen Jing Zheng Jianya Zhou Jianying Zhou 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第8期1156-1166,I0010-I0013,共11页
Objective:Osimertinib has demonstrated superior efficacy as a first-line treatment for epidermal growth factor receptor(EGFR)-mutated non-small cell lung cancer(NSCLC)in clinical trials.This study was aimed at providi... Objective:Osimertinib has demonstrated superior efficacy as a first-line treatment for epidermal growth factor receptor(EGFR)-mutated non-small cell lung cancer(NSCLC)in clinical trials.This study was aimed at providing real-world evidence of osimertinib treatment in Chinese populations.Methods:This prospective,multicenter,non-interventional study was conducted from July 27,2020,to April 27,2022.Treatmentnaive adults(≥18 years of age)with locally advanced or metastatic EGFR-mutated NSCLC scheduled to receive first-line osimertinib were included.Of 507 patients screened,481 were eligible in the full analysis set.The primary endpoint was time to treatment discontinuation(TTD).Secondary endpoints included real-world progression-free survival(rwPFS),overall survival(OS),objective response rate(ORR),disease control rate(DCR),and safety.Results:Among 481 patients(median age 64.1 years;62.2%women),the median follow-up was 31.3 months.The mTTD was 24.6 months(95%CI,22.4–26.7),the median rwPFS was 19.4 months(95%CI,16.2–20.4),and the mOS was 41.0 months[95%CI,39.7 to not reached(NR)].The mOS was 43.1 months(95%CI,39.7 to NR)in FLAURA-eligible patients vs.33.5 months(95%CI,26.8 to NR)in FLAURA-ineligible patients.The mOS was 29.3 months(95%CI:25.4 to NR)in patients with co-mutations vs.NR(95%CI:32.9 to NR)in the cohort with EGFR-only mutations.Adverse events occurred in 71.7%of patients,and grade≥3 events occurred in 11.4%.The safety profiles were similar between FLAURA-eligible and ineligible patients.Conclusions:First-line osimertinib demonstrated robust effectiveness and manageable safety in real-world Chinese patients with EGFR-mutated advanced NSCLC,including those ineligible for clinical trials.Patients with co-mutations showed diminished clinical benefit,thus suggesting a potential need for intensified treatment strategies in this population. 展开更多
关键词 Osimertinib epidermal growth factor receptor non-small cell lung cancer real-world co-mutations
暂未订购 下载PDF
Chemotherapy-free regimen:Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer 认领 引用
9
作者 Haiyang Chen Guanghua Yang +26 位作者 Tao Wang Gongbin Chen Aiguo Xu Chunzheng Ma Ke Shang Peijie Liu Honglin Zhou Zhiwei Wang Xinju Xu Xiao Sun Fengyu Zhai Yuanyuan Ji Juan Huangfu Xinli Jia Chunqing Li Jiazhuan Mei Minyong Jia Shunhai Niu Gaogao Zhang Yuqing Liu Lin Lu Juntao Zhang Lijun Wang Tianjiang Ma Liwei Gao Cailing Jin Qiming Wang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2026年第1期39-51,共13页
Objective:Chemotherapy-based regimens remain the standard first-and second-line treatment options for patients with driver gene-negative non-small cell lung cancer(NSCLC).However,in real-world settings,certain patient... Objective:Chemotherapy-based regimens remain the standard first-and second-line treatment options for patients with driver gene-negative non-small cell lung cancer(NSCLC).However,in real-world settings,certain patients cannot tolerate chemotherapy or opt to decline it.Immune checkpoint inhibitors(ICIs)constitute the preferred chemotherapy-free alternative.To enhance patient prognosis,this study aimed to examine the efficacy of ICIs combined with anlotinib in real-world scenarios.Methods:This prospective,multicenter,real-world study evaluated the efficacy and safety of ICIs combined with anlotinib in patients with advanced NSCLC.Patients undergoing first-or second-line treatment were enrolled.The primary endpoint was progression-free survival(PFS),while the secondary endpoints included overall survival(OS),objective response rate(ORR),disease control rate(DCR),and safety.Results:In total,242 patients were enrolled from 28 centers.The median PFS for the entire cohort was 7.8[95%confidence interval(95%CI),7.0-9.5]months,OS events occurred in 112(46.3%)patients,with a current median OS of 17.0(95%CI,15.1-19.4)months.The ORR and DCR were 36.0%(95%CI,30.2%-42.2%)and97.9%(95%CI,95.3%-99.1%),respectively.The median PFS was 9.8(95%CI,7.4-12.5)months for first-line therapy and 6.9(95%CI,6.0-8.3)months for second-line therapy.Treatment-related adverse events(AEs)occurred in 198(81.8%)patients,with grade 3-4 AEs reported in 22(9.1%)patients.Conclusions:This multicenter,real-world study demonstrates that the anlotinib-ICI combination regimen exhibits clinically meaningful efficacy and tolerability as a chemotherapy-free alternative for advanced NSCLC,offering viable evidence to guide treatment for patients who are unsuitable for conventional chemotherapy. 展开更多
关键词 Anlotinib anti-angiogenic drug immunotherapy non-small cell lung cancer chemotherapy-free
暂未订购 下载PDF
The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer 认领 引用
10
作者 Francesco Petrella Andrea Cara +5 位作者 Enrico Mario Cassina Lidia Libretti Emanuele Pirondini Federico Raveglia Maria Chiara Sibilia Antonio Tuoro 《Oncology Research》 SCIE 2026年第5期28-42,共15页
The advent of immune checkpoint inhibitors(ICIs)targeting PD-1,PD-L1,and CTLA-4 has transformed the therapeutic landscape of advanced non-small cell lung cancer(NSCLC),and recent clinical trials have extended their ap... The advent of immune checkpoint inhibitors(ICIs)targeting PD-1,PD-L1,and CTLA-4 has transformed the therapeutic landscape of advanced non-small cell lung cancer(NSCLC),and recent clinical trials have extended their application to resectable disease.Multiple randomized phase Ⅲ trials have demonstrated that neoadjuvant and adjuvant immunotherapy,particularly when combined with platinum-based chemotherapy,significantly improves pathological complete response(pCR),major pathological response(MPR),event-free survival(EFS),disease-free survival(DFS),and overall survival(OS)compared to chemotherapy alone.Several key questions remain unresolved—including whether preoperative or postoperative immunotherapy yields superior outcomes,whether adjuvant therapy provides additional benefit after neoadjuvant immune checkpoint inhibitors plus chemotherapy(ICI-CT),and how best to identify the patients most likely to benefit from each strategy.This review will critically examine the current evidence,clinical trial landscape,and future directions for immunotherapy in resectable NSCLC. 展开更多
关键词 Non-small cell lung cancer immunotherapy lung resection immune checkpoint inhibitors pathological response
暂未订购 下载PDF
Investigating the Immune Effects of Radiotherapy in Non-Small Cell Lung Cancer—Results of the PD-RAD Study 认领 引用
11
作者 Shuhui Cheng Tiana Kordbacheh +8 位作者 Antonia Banyard Anshuman Chaturvedi Diego Sanchez Martinez Crispin T.Hiley Maggie Harris Clara Chan Corinne Faivre-Finn Timothy M.Illidge Eleanor J.Cheadle 《Oncology Research》 SCIE 2026年第3期428-444,共17页
Objectives:The PACIFIC trial established the benefit of durvalumab following chemo-radiotherapy for stage III non-small cell lung cancer(NSCLC).However,the concurrent use of radiotherapy(RT)and durvalumab(PACIFIC-2 tr... Objectives:The PACIFIC trial established the benefit of durvalumab following chemo-radiotherapy for stage III non-small cell lung cancer(NSCLC).However,the concurrent use of radiotherapy(RT)and durvalumab(PACIFIC-2 trial)showed no additional advantage.The PD-RAD study was set up to understand the immunological effects of RT on the tumor microenvironment(TME)to aid in optimizing sequencing of combination therapies.Methods:The PD-RAD trial(ClinicalTrials.gov identifier:NCT03258788)aimed to enroll thirty NSCLC patients receiving radical-intent RT.Tumor biopsies and blood samples were collected pre-RT and at week 2 during RT and analyzed using multiplex immunohistochemistry(mIHC)and high-dimensional mass cytometry(CyTOF),respectively.Results:Paired biopsies were collected from only three patients(Pts 1,3&4)and blood from four patients(Pts 1-4)before the study was closed early during the COVID-19 pandemic.Programmed Death-Ligand 1(PD-L1)expression in the TME was raised in Patient 1,who responded well to treatment,and unaltered in two patients with progressive disease.CyTOF analysis revealed elevated circulating classical monocytes,highest in the patient with a good response.Conclusions:This study underscores the challenges of integrating advanced immune monitoring during RT delivery and did not meet its primary endpoint.The hypothesis-generating findings highlight PD-L1+macrophages in the TME and classical monocytes in the blood as potential immune biomarkers of RT response,but larger studies are needed to validate these observations and characterize the immune changes following curative-intent RT in patients with NSCLC. 展开更多
关键词 Non-small cell lung cancer(NSCLC) radiotherapy tumor microenvironment biomarker programmed death-ligand 1(PD-L1) classical monocytes
暂未订购 下载PDF
Engineering the Future of ADCs in Non-Small Cell Lung Cancer 认领 引用
12
作者 Mi Rim Kim Jason Lau +1 位作者 Michele Maffezzoli Giuseppe Luigi Banna 《Oncology Research》 SCIE 2026年第7期40-65,共26页
Antibody–drug conjugates(ADCs)are a promising strategy in non-small cell lung cancer(NSCLC),but early-generation drugs were limited by suboptimal target selection,heterogeneous drug–antibody ratios,and linker instab... Antibody–drug conjugates(ADCs)are a promising strategy in non-small cell lung cancer(NSCLC),but early-generation drugs were limited by suboptimal target selection,heterogeneous drug–antibody ratios,and linker instability,resulting in modest efficacy and relevant toxicities.We performed a narrative review based on a literature search of PubMed and major oncology congresses up to October 2025,with the aim to critically analyzing the evolving biomarker landscape and engineering strategies shaping next-generation ADC development in NSCLC.Emerging approaches to identify targets for ADCs and refine patient selection include digital pathology with artificial intelligence technologies,transcriptomic and proteomic profiling,and liquid biopsy.Modern platforms incorporate site-specific conjugation technologies to achieve controlled and homogeneous drug-to-antibody ratio(DAR)distributions,improving pharmacokinetic predictability and reducing off-target effects.Advances in linker chemistry enhance plasma stability while preserving efficient intracellular payload release,balancing bystander effect with safety.These innovations are designed to enhance tumor selectivity,mitigate off-target toxicity and overcome resistance mechanisms.In conclusion,next-generation ADCs in NSCLC integrate refined biomarker strategies with advances in antibody engineering,linker design and payload biology.Emerging approaches,including immune-stimulating and bispecific ADCs,novel payloads,and combinations with tyrosine kinase inhibitors(TKIs)or immunotherapy,may improve efficacy,overcome resistance and expand the therapeutic window.Bispecific and dual-payload ADCs,as well as immune-stimulating ADCs,further aim to overcome resistance,exploiting both direct cytotoxicity and immune system activation and positioning ADCs as a crucial component of precision oncology in NSCLC. 展开更多
关键词 Antibody–drug conjugates(ADCs) non-small cell lung cancer(NSCLC) biomarker linker payload bispecific
暂未订购 下载PDF
Factors Affecting the Efficacy and Safety of First-Line Anti-PD-1 Therapy in Advanced Non-Small Cell Lung Cancer 认领 引用
13
作者 Zhen Wang Qian Xie +4 位作者 Yu Luo Chuan Li Wenqiang Guan Yanling Zhang Jidong Miao 《Oncology Research》 SCIE 2026年第7期651-665,共15页
Objective:This study assesses peripheral blood parameters as predictors of programmed cell death protein-1(PD-1)inhibitor efficacy in advanced non-small cell lung cancer(NSCLC).Methods:We retrospectively analyzed 169 ... Objective:This study assesses peripheral blood parameters as predictors of programmed cell death protein-1(PD-1)inhibitor efficacy in advanced non-small cell lung cancer(NSCLC).Methods:We retrospectively analyzed 169 advanced NSCLC patients receiving first-line PD-1 inhibitor-based therapy.Baseline blood parameters and clinical characteristicswere recorded.Logistic regression assessed associations with immune-related adverse events(irAEs).Chi-square tests compared efficacy and safety across treatment groups.Results:Baseline albumin/fibrinogen ratio(ALB/FIB)and PIV were associated with all-grade irAEs(p<0.05),while PIV was markedly associated with grade≥3 irAEs(p<0.01).Multivariate analysis identified that the baseline pan-immune inflammation value(PIV)was independently associated with the occurrence of irAEs(p<0.01).Compared to PD-1 inhibitor plus chemotherapy,adding bevacizumab increased oral mucositis(p=0.010)and was linked to a later clinical stage(p=0.001).In patients receiving peri-immunotherapy radiotherapy,leukopenia was more frequent(p=0.030).Conclusion:Baseline PIV is independently associated with the occurrence of irAEs in advanced NSCLC patients receiving first-line PD-1 inhibitor therapy.Adding bevacizumab or radiotherapy may modify safety profiles. 展开更多
关键词 Advanced non-small cell lung cancer PD-1 inhibitors safety immune-related adverse events prognosis
暂未订购 下载PDF
Utilization of a UPLC-MS/MS Approach to Elucidate the Role of ABCB1-Mediated Paclitaxel Resistance in Non-Small Cell Lung Cancer Cells 认领 引用
14
作者 Sha Hu Wenjing Wang +6 位作者 Qianfang Hu Rujuan Zheng Qinghe Huang Hui Shi Xinyuan Ding Wenjuan Wang Zengyan Zhu 《Oncology Research》 SCIE 2026年第2期402-423,共22页
Objectives:Acquired resistance to paclitaxel represents a critical barrier to the effective chemotherapy of non-small cell lung cancer(NSCLC).The present study aimed to elucidate the molecular and pharmacological mech... Objectives:Acquired resistance to paclitaxel represents a critical barrier to the effective chemotherapy of non-small cell lung cancer(NSCLC).The present study aimed to elucidate the molecular and pharmacological mechanisms promoting paclitaxel resistance in NSCLC and to explore potential strategies for overcoming this resistance.Methods:Here,we report an integrated pharmacological and analytical approach to quantify paclitaxel disposition and overcome resistance in a A549/TAX cell model(paclitaxel-resistant A549 cells).Results:Cell counting kit-8(CCK-8)assay,colony formation,and apoptosis assays confirmed that A549/TAX cells exhibited marked resistance to paclitaxel relative to parental A549 cells.Based on transcriptome profiling by RNA sequencing analysis and validation by western blotting assay,we found that the expression of the ATP-binding cassette subfamily B member 1(ABCB1)(the encoded protein is termed P-glycoprotein)was significantly upregulated in resistant cells.By using ultra performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS),we demonstrated that ABCB1 overexpression promotes enhanced efflux of intracellular paclitaxel,thereby lowering its cytotoxic accumulation.Genetic silencing of ABCB1 or pharmacological inhibition with the specific P-glycoprotein modulator elacridar or tariquidar restored intracellular paclitaxel levels,as determined by UPLC-MS/MS,and synergistically decreased cell viability as observed in CCK-8 assay.Conclusion:These findings reveal that the ABCB1-mediated drug efflux is a crucial mechanism underlying paclitaxel resistance in NSCLC cells,with UPLC-MS/MS serving as a sensitive analytical method to detect paclitaxel concentration.Inhibition of ABCB1 is a promising therapeutic strategy to resensitize resistant tumor cells to paclitaxel. 展开更多
关键词 Non-small cell lung cancer(NSCLC) chemoresistance paclitaxel ATP-binding cassette subfamily B member 1(ABCB1) ultra performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS)
暂未订购 下载PDF
RP3-340N1.2 Knockdown Suppresses Proliferation and Migration by Downregulating IL-6 in Non-Small Cell Lung Cancer 认领 引用
15
作者 Hang Zhang Meng-yuan Chu +4 位作者 Guohui Lv You-JieLi Xuhang Liu Fei Jiao Yun-Fei Yan 《BIOCELL》 SCIE 2026年第1期212-231,共20页
Objectives:Non-small cell lung cancer(NSCLC)remains a leading cause of cancer-related mortality,with limited understanding of lncRNA-driven mechanisms in tumor progression.This study aimed to identify differentially e... Objectives:Non-small cell lung cancer(NSCLC)remains a leading cause of cancer-related mortality,with limited understanding of lncRNA-driven mechanisms in tumor progression.This study aimed to identify differentially expressed lncRNAs in NSCLC tissues and elucidate the functional role of the significantly upregulated RP3-340N1.2 in promoting malignancy.Methods:RNA sequencing was used to screen dysregulated lncRNAs.RP3-340N1.2 was functionally characterized via gain/loss-of-function assays in NSCLC cells,assessing proliferation,migration,and macrophage polarization.Mechanisms of interleukin 6(IL-6)regulation were explored using cytokine profiling,Actinomycin D assays,and RNA Immunoprecipitation(RIP)assays to study RP3-340N1.2 interactions with zinc finger CCCH-type containing 12A(ZC3H12A)and IL-6 mRNA.Results:RP3-340N1.2 was upregulated in NSCLC tissues and cells.Functional assays demonstrated that RP3-340N1.2 knockdown suppressed NSCLC cell proliferation/migration and reduced macrophage polarization toward tumor-associated phenotypes.Mechanistically,RP3-340N1.2 knockdown promoted IL-6 mRNA degradation,as supported by reduced IL-6 levels and accelerated mRNA decay.Further RIP assays revealed that RP3-340N1.2 interacts with ZC3H12A,an RNA-binding protein previously reported to degrade IL-6 mRNA,and that RP3-340N1.2 knockdown enhanced ZC3H12A binding to IL-6 mRNA.Consequently,RP3-340N1.2 knockdown in carcinoma cells attenuated IL-6-mediated tumor-promoting effects,including tumor cell proliferation and migration.Importantly,these effectswere observed not only in a direct carcinoma cell culturing system but also when carcinoma cells were exposed to conditioned medium from co-culturing RP3-340N1.2-knockdown tumor cells andmacrophages.Conclusion:RP3-340N1.2 drivesNSCLC malignancy by stabilizing IL-6 mRNA;its inhibition offers a potential therapeutic strategy to disrupt tumor-promoting interactions. 展开更多
关键词 RP3-340N1.2 interleukin 6(IL-6) zinc finger CCCH-type containing 12A(ZC3H12A) non-small cell lung cancer tumor associated macrophage
暂未订购 下载PDF
Multidimensional mechanisms of drug resistance in non-small cell lung cancer and novel strategies for overcoming it 认领 引用
16
作者 Xiang-Yi Zhang Xin-Yu Pan +6 位作者 Yong Zhu Min Hu Shuo Ma Si-Yan Zheng Ci-Hang Wu Yi-Luo Xie Yi-Chi Xie 《World Journal of Clinical Oncology》 2026年第7期50-69,共20页
Non-small cell lung cancer(NSCLC)has entered the era of precision medicine across all driver mutation subtypes and treatment settings;However,drug resistance mechanisms differ substantially across molecular subtypes a... Non-small cell lung cancer(NSCLC)has entered the era of precision medicine across all driver mutation subtypes and treatment settings;However,drug resistance mechanisms differ substantially across molecular subtypes and therapeutic contexts,and resistance remains a central challenge in routine clinical practice.The development of resistance is a complex,multidimensional,and spatiotemporally heterogeneous process involving the intrinsic genetic and epigenetic characteristics of tumor cells,the dynamic remodeling of the tumor microenvironment,and systemic host factors.This article summarizes the latest research advances in treatment resistance in NSCLC,delving deeply into the multidimensional nature of resistance across five dimensions:Molecular mechanisms and spatial heterogeneity,the temporal dynamics of resistance,heterogeneity of the tumor immune microenvironment,novel therapeutic strategies,and future directions for multi-omics integration.The review focuses on synergistic inhibition strategies targeting“undruggable”targets,monitoring the evolution of resistant clones via liquid biopsy,precision interventions based on immune microenvironment stratification,breakthroughs in novel therapeutic modalities such as antibody-drug conjugates,and how to utilize multi-omics data and advanced computational models to achieve personalized diagnosis and treatment.This article aims to provide a systematic theoretical framework and innovative solutions for understanding and overcoming treatment resistance in NSCLC. 展开更多
关键词 Non-small lung cancer Cancer Drug Multidimensional mechanisms Novel strategies
暂未订购 下载PDF
Cancer stem cell-associated markers and their prognostic value in non-small cell lung cancer 认领 引用
17
作者 Lin-Lin Luo Si-Cong Jiang +3 位作者 Shuo Li Guang-Yi Zhang Jian-Jun Tang You-Dan Guo 《World Journal of Stem Cells》 SCIE 2026年第6期81-91,共11页
BACKGROUND An urgent clinical need exists to stratify postoperative prognosis in patients with non-small cell lung cancer(NSCLC).However,the prognostic value of the cancer stem cell(CSC)markers CD133,aldehyde dehydrog... BACKGROUND An urgent clinical need exists to stratify postoperative prognosis in patients with non-small cell lung cancer(NSCLC).However,the prognostic value of the cancer stem cell(CSC)markers CD133,aldehyde dehydrogenase 1A1(ALDH1A1),and SRY-box transcription factor 2(SOX2)remains incompletely characterized.These markers are better viewed as complementary biomarkers for postoperative risk enrichment than as replacements for tumor-node-metastasis(TNM)staging or molecular classification.AIM To investigate expression levels of CD133,ALDH1A1 and SOX2,markers related to CSC,in NSCLC tissues for postoperative survival and prognosis.METHODS A total of 200 patients with pathologically confirmed NSCLC who underwent radical resection at Jiangxi Provincial People’s Hospital(The First Affiliated Hospital of Nanchang Medical College)between January 2023 and December 2025 were included retrospectively.Expressions of CD133,ALDH1A1,and SOX2 in tumor tissues was detected by immunohistochemistry,and the tumors were divided into high-and low-expression groups according to the immunoreactive score.All patients were followed up until December 2025 to record their overall survival(OS)and disease-free survival(DFS).The t-test orχ2 test was used for comparison between groups.The Kaplan-Meier method and log-rank test were used for survival analysis.Univariate and multivariate analyses were performed using a Cox proportional risk model,and a prognostic model including CSC markers was constructed to evaluate the C-index and area under the curve of the receiver operating characteristic curve for 2-year OS.The immunoreactive score cut-off selection was based on prior literature and cohort distribution rather than on receiver operating characteristic derivation.DFS was analyzed as a conventional composite endpoint and model discrimination was internally corrected using bootstrap resampling.RESULTS Among 200 patients,the high expression rates of CD133,ALDH1A1,and SOX2 were 44.00%(88/200),53.00%(106/200),and 40.00%(80/200),respectively.The median follow-up period was 23.50 months(interquartile range:14.20-31.60 months),resulting in 54 deaths(27.00%)and 70 recurrences/metastases(35.00%).After adjusting for age,gender,smoking history,histological type,differentiation degree,TNM stage,and adjuvant therapy,high expression of CD133[hazard ratio(HR)=1.450,95%confidence interval(CI):1.033-2.037,P=0.032],high expression of ALDH1A1(HR=1.380,95%CI:1.001-1.902,P=0.049),and TNM stage III(HR=1.980,95%CI:1.235-3.173,P=0.004 compared to stage I)were independent adverse prognostic factors for OS.Patients with CSC score≥2 had significantly shorter OS(P=0.004),and this association remained significant in the multivariate model(HR=1.550,95%CI:1.078-2.228,P=0.018).After adding the CSC score,the predicted area under the curve value for 2-year OS increased from 0.675 to 0.785.CONCLUSION High expressions of CD133 and ALDH1A1 in NSCLC suggests a worse survival outcome.Nonetheless,the CSC score should be interpreted together with the TNM stage,histological background,and molecular features rather than used in isolation for clinical decision-making. 展开更多
关键词 Non-small cell lung cancer Cancer stem cells CD133 Aldehyde dehydrogenase 1A1 SRY-box transcription factor 2 Prognosis
暂未订购 下载PDF
Research on the Resistance Mechanism of Third-generation EGFR-TKIs in Non-Small Cell Lung Cancer 认领 引用
18
作者 Ting Zhong Chunchu Kong 《Proceedings of Anticancer Research》 2026年第2期32-40,共9页
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-Tkis)represented by osimertinib have become the first-line standard treatment option for EGFR-mutated non-small cell lung cancer(NSCLC)... Third-generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-Tkis)represented by osimertinib have become the first-line standard treatment option for EGFR-mutated non-small cell lung cancer(NSCLC),significantly improving progression-free survival and overall survival in patients.However,almost all patients eventually develop acquired resistance,which severely limits the long-term efficacy.This article systematically reviews the main molecular mechanisms of resistance to third-generation EGFR-Tkis and the latest research progress.Existing evidence suggests that resistance mechanisms can be roughly divided into two major categories:EGFR-dependent(on-target)and EGFR-independent(off-target).EGFR-dependent resistance mainly includes secondary mutations such as C797S,mutations in other kinase domains,and EGFR gene amplification,which directly affect drug binding to the target.Egfr-independent resistance is more complex,involving bypass signaling pathway activation(such as MET amplification,HER2 or AXL abnormalities),histological transformation(such as adenocarcinoma to small cell lung cancer transformation),downstream signaling pathway abnormalities(RAS/MAPK,PI3K/AKT pathways),and cell cycle regulation imbalance.In addition,recent studies have further revealed the important roles of metabolic reprogramming,epigenetic regulation,tumor-microenvironment interactions,and drug-resistant persistent cells in the formation of resistance.In terms of therapeutic strategies,novel approaches such as combined targeted therapy for resistance mechanisms,next-generation EGFR inhibitors,bispecific antibodies,antibody-drug conjugations,immunotherapy and cell therapy are advancing and showing good clinical prospects in some patients.Overall,third-generation EGFR-TKI resistance shows high heterogeneity and dynamic evolution characteristics,and in the future,multi-omics detection,dynamic molecular monitoring,and individualized combination therapy strategies will be needed to achieve more precise and durable disease control. 展开更多
关键词 Non-small cell lung cancer EGFR mutations Third-generation EGFR-TKI Osimertinib Acquired resistance Bypass signaling pathways
暂未订购 下载PDF
Clinical Review on Perioperative Immunotherapy Patterns for Non-Small Cell Lung Cancer 认领 引用
19
作者 Shaoyong Dong Jing Sun Ying Yang 《Proceedings of Anticancer Research》 2026年第3期42-47,共6页
The application scope of immunotherapy has gradually expanded from advanced non-small cell lung cancer to the perioperative stage,with three core clinical application forms progressively established:neoadjuvant therap... The application scope of immunotherapy has gradually expanded from advanced non-small cell lung cancer to the perioperative stage,with three core clinical application forms progressively established:neoadjuvant therapy,adjuvant therapy,and comprehensive management combining neoadjuvant and adjuvant approaches.Recent clinical studies have demonstrated that all three treatment modalities can achieve improvements in pathological response and event-free survival.However,consensus remains elusive regarding the characteristics of beneficiary populations,efficacy differences among various treatment strategies,and perioperative-specific safety risks.By integrating recent clinical research findings and systematically reviewing evidence-based data for each therapeutic approach,this review aims to provide evidence-based support for rational clinical treatment selection. 展开更多
关键词 Non-small cell lung cancer Perioperative period Immunotherapy Treatment modality Immune-related adverse reactions
暂未订购 下载PDF
The influence of single-port thoracoscopic lobectomy on pulmonary ventilation-related indicators in patients with non-small cell lung cancer 认领 引用
20
作者 XU Hong 《外文科技期刊数据库（文摘版）医药卫生》 2026年第4期128-133,共6页
Objective: This study explores the impact of single-port thoracoscopic lobectomy on pulmonary ventilation-related indicators in patients with non-small cell lung cancer, aiming to provide evidence-based basis for opti... Objective: This study explores the impact of single-port thoracoscopic lobectomy on pulmonary ventilation-related indicators in patients with non-small cell lung cancer, aiming to provide evidence-based basis for optimizing clinical surgical plans. A total of 80 patients with stage I-II NSCLC who underwent surgery were selected and randomly divided into the observation group (SP-VATS) and the control group (traditional three-port thoracoscopic surgery). The pulmonary function and arterial blood gas indicators of the two groups before 1 day, 3 days, 7 days, and 1 month after surgery were compared, and the surgical-related indicators and complications were recorded. Results: The operation time, intraoperative blood loss, chest tube retention time, and hospital stay of the observation group were significantly better than those of the control group (P < 0.05);at each postoperative time point, the lung function indicators such as FEV₁, FVC, MVV, PEF, and DLCO and the PaO₂, SaO₂ of the observation group were significantly higher than those of the control group, and PaCO₂ was significantly lower than that of the control group (P < 0.05);the total incidence of complications in the observation group was lower than that in the control group (P < 0.05). Conclusion: SP-VATS treatment for NSCLC causes less trauma, causes less damage to the patient's pulmonary function, leads to faster postoperative recovery and fewer complications, is more conducive to postoperative respiratory rehabilitation of patients, and is worthy of clinical promotion. 展开更多
关键词 Single-port thoracoscopy Non-small cell lung cancer Lobectomy Pulmonary ventilation function
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 250 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈